Associated Papers
Pachydermoperiostosis Associated With a Rare SLCO2A1 Mutation: A Case Report and Literature Review.
Mohammad M et al.
Cureus, 2025
Structure and transport mechanism of the human prostaglandin transporter SLCO2A1.
Xia Z et al.
Nature Communications, 2025
Genotype and phenotype characterization of primary hypertrophic osteoarthropathy type 2 and chronic enteropathy associated with SLCO2A1: Report of two cases and literature review.
Kimball TN et al.
American Journal of Medical Genetics. Part A, 2024
Recent advances in studies of SLCO2A1 as a key regulator of the delivery of prostaglandins to their sites of action.
Nakanishi T et al.
Pharmacology & Therapeutics, 2021
Interleukin-6, tumor necrosis factor-alpha and receptor activator of nuclear factor kappa ligand are elevated in hypertrophic gastric mucosa of pachydermoperiostosis.
Huang H et al.
Scientific Reports, 2017
28851954 (PubMed )
Supplement: 41598_2017_9671_MOESM1_ESM.pdf
Clinical, Biochemical, and Genetic Features of 41 Han Chinese Families With Primary Hypertrophic Osteoarthropathy, and Their Therapeutic Response to Etoricoxib: Results From a Six-Month Prospective Clinical Intervention.
Li SS et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, 2017
Identification of two novel mutations in the SLCO2A1 prostaglandin transporter gene in a Chinese patient with primary hypertrophic osteoarthropathy.
Guo T et al.
Molecular Medicine Reports, 2017
Identification of the Mutations in the Prostaglandin Transporter Gene, SLCO2A1 and Clinical Characterization in Korean Patients with Pachydermoperiostosis.
Lee S et al.
Journal of Korean Medical Science, 2016
The novel SLCO2A1 heterozygous missense mutation p.E427K and nonsense mutation p.R603* in a female patient with pachydermoperiostosis with an atypical phenotype.
Niizeki H et al.
The British Journal of Dermatology, 2014
Select a paper to view details